scholarly journals What Was First, Obesity or Inflammatory Bowel Disease? What Does the Gut Microbiota Have to Do with It?

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3073
Author(s):  
Sara Jarmakiewicz-Czaja ◽  
Aneta Sokal ◽  
Rafał Filip
Keyword(s):  
Gut Microbiota ◽  
Response To Treatment ◽  
Excess Body Weight ◽  
Additional Risk Factor ◽  
Additional Risk ◽  
Bowel Diseases ◽  
Negative Effect ◽  
Inflammatory Bowel ◽  
Inadequate Nutrition ◽  
Desirable Effect

A sedentary lifestyle and inadequate nutrition often leads to disturbances in intestinal homeostasis, which may predispose people to excess body weight and metabolic syndrome. Obesity is frequently observed in patients with inflammatory bowel diseases (IBD), similar to the general population. Obesity may exert a negative effect on the course of IBD as well as reduce the response to treatment. Moreover, it may also be an additional risk factor for vein thromboembolism during the flare. In both obesity and IBD, it is of great importance to implement proper dietary ingredients that exert desirable effect on gut microbiota. The key to reducing body mass index (BMI) and alleviating the course of IBD is preserving healthy intestinal microflora.

scholarly journals Psoriasis and Gut Microbiome—Current State of Art

2021 ◽  
Vol 22 (9) ◽  
pp. 4529
Author(s):  
Karina Polak ◽  
Beata Bergler-Czop ◽  
Michał Szczepanek ◽  
Kamila Wojciechowska ◽  
Aleksandra Frątczak ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Gut Microbiome ◽  
Response To Treatment ◽  
Current State ◽  
Immune Mediated ◽  
Bowel Diseases ◽  
Triggering Factor ◽  
Inflammatory Bowel ◽  
The Relationship ◽  
Gut Microbiota Composition

Psoriasis is a chronic, immune-mediated inflammatory disease that affects around 125 million people worldwide. Several studies concerning the gut microbiota composition and its role in disease pathogenesis recently demonstrated significant alterations among psoriatic patients. Certain parameters such as Firmicutes/Bacteroidetes ratio or Psoriasis Microbiome Index were developed in order to distinguish between psoriatic and healthy individuals. The “leaky gut syndrome” and bacterial translocation is considered by some authors as a triggering factor for the onset of the disease, as it promotes chronic systemic inflammation. The alterations were also found to resemble those in inflammatory bowel diseases, obesity and certain cardiovascular diseases. Microbiota dysbiosis, depletion in SCFAs production, increased amount of produced TMAO, dysregulation of the pathways affecting the balance between lymphocytes populations seem to be the most significant findings concerning gut physiology in psoriatic patients. The gut microbiota may serve as a potential response-to-treatment biomarker in certain cases of biological treatment. Oral probiotics administration as well as fecal microbial transplantation were most reported in bringing health benefits to psoriatic patients. However, the issue of psoriatic bacterial gut composition, its role and healing potential needs further investigation. Here we reviewed the literature on the current state of the relationship between psoriasis and gut microbiome.

scholarly journals Mediterranean Diet to Prevent the Development of Colon Diseases: A Meta-Analysis of Gut Microbiota Studies

Nutrients ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 2234
Author(s):  
Oscar Illescas ◽  
Miriam Rodríguez-Sosa ◽  
Manuela Gariboldi
Keyword(s):  
Gut Microbiota ◽  
Mediterranean Diet ◽  
Meta Analysis ◽  
Intestinal Barrier ◽  
Preventive Measure ◽  
Bowel Diseases ◽  
Preventive Method ◽  
Inflammatory Bowel ◽  
Colon Diseases ◽  
Cancer And Inflammation

Gut microbiota dysbiosis is a common feature in colorectal cancer (CRC) and inflammatory bowel diseases (IBD). Adoption of the Mediterranean diet (MD) has been proposed as a therapeutic approach for the prevention of multiple diseases, and one of its mechanisms of action is the modulation of the microbiota. We aimed to determine whether MD can be used as a preventive measure against cancer and inflammation-related diseases of the gut, based on its capacity to modulate the local microbiota. A joint meta-analysis of publicly available 16S data derived from subjects following MD or other diets and from patients with CRC, IBD, or other gut-related diseases was conducted. We observed that the microbiota associated with MD was enriched in bacteria that promote an anti-inflammatory environment but low in taxa with pro-inflammatory properties capable of altering intestinal barrier functions. We found an opposite trend in patients with intestinal diseases, including cancer. Some of these differences were maintained even when MD was compared to healthy controls without a defined diet. Our findings highlight the unique effects of MD on the gut microbiota and suggest that integrating MD principles into a person’s lifestyle may serve as a preventive method against cancer and other gut-related diseases.

scholarly journals The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease

2019 ◽  
Vol 12 ◽  
pp. 175628481882225 ◽  
Author(s):  
Jonathan P. Segal ◽  
Benjamin H. Mullish ◽  
Mohammed Nabil Quraishi ◽  
Animesh Acharjee ◽  
Horace R. T. Williams ◽  
...  
Keyword(s):  
Systems Biology ◽  
Gut Microbiota ◽  
Potential Role ◽  
Intestinal Inflammation ◽  
Clinical Care ◽  
Complex Interaction ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Compositional Changes

The aetiopathogenesis of inflammatory bowel diseases (IBD) involves the complex interaction between a patient’s genetic predisposition, environment, gut microbiota and immune system. Currently, however, it is not known if the distinctive perturbations of the gut microbiota that appear to accompany both Crohn’s disease and ulcerative colitis are the cause of, or the result of, the intestinal inflammation that characterizes IBD. With the utilization of novel systems biology technologies, we can now begin to understand not only details about compositional changes in the gut microbiota in IBD, but increasingly also the alterations in microbiota function that accompany these. Technologies such as metagenomics, metataxomics, metatranscriptomics, metaproteomics and metabonomics are therefore allowing us a deeper understanding of the role of the microbiota in IBD. Furthermore, the integration of these systems biology technologies through advancing computational and statistical techniques are beginning to understand the microbiome interactions that both contribute to health and diseased states in IBD. This review aims to explore how such systems biology technologies are advancing our understanding of the gut microbiota, and their potential role in delineating the aetiology, development and clinical care of IBD.

scholarly journals The Use of Probiotic Therapy to Modulate the Gut Microbiota and Dendritic Cell Responses in Inflammatory Bowel Diseases

2019 ◽  
Vol 7 (2) ◽  
pp. 33 ◽  
Author(s):  
Pablo Alagón Fernández del Campo ◽  
Alejandro De Orta Pando ◽  
Juan Ignacio Straface ◽  
José Ricardo López Vega ◽  
Diego Toledo Plata ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Inflammatory Bowel Diseases ◽  
T Regulatory Cells ◽  
Oxygen Species ◽  
Regulatory Cells ◽  
Population Status ◽  
Cell Responses ◽  
Bowel Diseases ◽  
Tolerance Response ◽  
Inflammatory Bowel

: Recent investigations have shown that different conditions such as diet, the overuse of antibiotics or the colonization of pathogenic microorganisms can alter the population status of the intestinal microbiota. This modification can produce a change from homeostasis to a condition known as imbalance or dysbiosis; however, the role-played by dysbiosis and the development of inflammatory bowel diseases (IBD) has been poorly understood. It was actually not until a few years ago that studies started to develop regarding the role that dendritic cells (DC) of intestinal mucosa play in the sensing of the gut microbiota population. The latest studies have focused on describing the DC modulation, specifically on tolerance response involving T regulatory cells or on the inflammatory response involving reactive oxygen species and tissue damage. Furthermore, the latest studies have also focused on the protective and restorative effect of the population of the gut microbiota given by probiotic therapy, targeting IBD and other intestinal pathologies. In the present work, the authors propose and summarize a recently studied complex axis of interaction between the population of the gut microbiota, the sensing of the DC and its modulation towards tolerance and inflammation, the development of IBD and the protective and restorative effect of probiotics on other intestinal pathologies.

scholarly journals Vitamin D Modulates Intestinal Microbiota in Inflammatory Bowel Diseases

2020 ◽  
Author(s):  
Carolina Battistini ◽  
Rafael Ballan ◽  
Marcos Herkenhoff ◽  
Susana Saad ◽  
Jun Sun
Keyword(s):  
Vitamin D ◽  
Gut Microbiota ◽  
Disease Activity ◽  
Chronic Inflammation ◽  
Immune Cell ◽  
Future Directions ◽  
Dihydroxyvitamin D3 ◽  
Host Interactions ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal0 tract (GIT), including Crohn’s disease (CD) and ulcerative colitis (UC), which differ in the location and lesion extensions. Both diseases are associated with microbiota dysbiosis, with a reduced population of butyrate-producing species, abnormal inflammatory response, and micronutrient deficiency (e. g. vitamin D hypovitaminosis). Vitamin D (VitD) is involved in immune cell differentiation, gut microbiota modulation, gene transcription, and barrier integrity. Vitamin D receptor (VDR) regulates the biological actions of the active VitD (1α, 25-dihydroxyvitamin D3), and is involved in the genetic, environmental, immune, and microbial aspects of IBD. VitD deficiency is correlated with disease activity and its administration targeting a concentration of 30 ng/mL may have the potential to reduce disease activity. Moreover, VDR regulates functions of T cells and Paneth cells and modulates release of antimicrobial peptides in gut microbiota-host interactions. Meanwhile, beneficial microbial metabolites, e.g. butyrate, upregulate the VDR signaling. In this review, we summarize the clinical progress and mechanism studies on VitD /VDR related to gut microbiota modulation in IBD. We also discuss epigenetics in IBD and the probiotic regulation of VDR. Furthermore, we discuss the existing challenges and future directions. There is a lack of well-designed clinical trials exploring the appropriate dose and the influence of gender, age, ethnicity, genetics, microbiome, and metabolic disorders in IBD subtypes. To move forward, we need well-designed therapeutic studies to examine whether enhanced vitamin D will restore functions of VDR and microbiome in inhibiting chronic inflammation.

scholarly journals Cross-Study Analyses of Gut Microbiomes from Healthy and Obese Individuals

2020 ◽  
Author(s):  
Maxime Deraspe ◽  
Charles Burdet ◽  
Juan Manuel Dominguez ◽  
François Laviolette ◽  
Paul H Roy ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Inflammatory Bowel Diseases ◽  
Normal Subjects ◽  
Health Conditions ◽  
Colorectal Cancers ◽  
Functional Composition ◽  
Potential Implication ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract Background: With the advent of metagenomics, many large studies have been conducted with the quest of better understanding gut microbiota changes in relation to varying health conditions. Significant findings have been made for diseases such as cirrhosis, colorectal cancers, inflammatory bowel diseases and others, yet one that stands out is obesity for which conflicting results have been reported in the literature. Methods: Here, we built and analyzed a cross-study dataset of healthy and obese individuals looking for major changes in the the taxonomic and functional composition of their metagenomes. Results: Our results suggest that the overweight and normal subjects have no strong dissimilarity in their metagenomes composition. Significant differences were observed when comparing the obese and the non-obese individuals in their functional and taxonomic profiles. Conclusion: In this study, we report the most significant changes that we observed and discuss their potential implication in the obesity condition.

scholarly journals Metagenomic alterations in gut microbiota precede and predict onset of colitis in the IL10 gene-deficient murine model

2020 ◽  
Author(s):  
Jun Miyoshi ◽  
Sonny T. M. Lee ◽  
Megan Kennedy ◽  
Mora Puertolas ◽  
Mary Frith ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Clinical Outcomes ◽  
Murine Model ◽  
Inflammatory Bowel Diseases ◽  
Gut Microbiome ◽  
Predictive Biomarkers ◽  
Disease Outcomes ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Robust Measures

AbstractBackground & AimsInflammatory bowel diseases (IBD) are chronic inflammatory disorders where predictive biomarkers for the disease development and clinical course are sorely needed for development of prevention and early intervention strategies that can be implemented to improve clinical outcomes. Since gut microbiome alterations can reflect and/or contribute to impending host health changes, we examined whether gut microbiota metagenomic profiles would provide more robust measures for predicting disease outcomes in colitis-prone hosts.MethodsUsing the IL-10 gene-deficient (IL-10 KO) murine model where early life dysbiosis from antibiotic (cefoperozone, CPZ) treated dams vertically-transferred to pups increases risk for colitis later in life, we investigated temporal metagenomic profiles in the gut microbiota of post-weaning offspring and determined their relationship to eventual clinical outcomes.ResultsCompared to controls, offspring acquiring maternal CPZ-induced dysbiosis exhibited a restructuring of intestinal microbial membership both in bacteriome and mycobiome that were associated with alterations in specific functional subsystems. Furthermore, among IL-10 KO offspring from CPZ-treated dams, several functional subsystems, particularly nitrogen metabolism, diverged between mice that developed spontaneous colitis (CPZ-colitis) versus those that did not (CPZ-no-colitis) at a time point prior to eventual clinical outcome.ConclusionsOur findings provide support that functional metagenomic profiling of gut microbes has potential and promise meriting further study for development of tools to assess risk and manage human IBD.SynopsisCurrently, predictive markers for the development and course of inflammatory bowel diseases (IBD) are not available. This study supports the notion that gut microbiome metagenomic profiles could be developed into a useful tool to assess risk and manage human IBD.

Sign in / Sign up

Export Citation Format

Share Document